BRPI0511253A - composição farmacêutica - Google Patents
composição farmacêuticaInfo
- Publication number
- BRPI0511253A BRPI0511253A BRPI0511253-2A BRPI0511253A BRPI0511253A BR PI0511253 A BRPI0511253 A BR PI0511253A BR PI0511253 A BRPI0511253 A BR PI0511253A BR PI0511253 A BRPI0511253 A BR PI0511253A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- diluent
- pharmaceutically acceptable
- acceptable salt
- substantially insoluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
COMPOSIçãO FARMACêUTICA. Uma composição farmacêutica contendo ZD6474 ou um seu sal farmaceuticamente aceitável, um diluente quebradiço e um segundo diluente que é praticamente insolúvel e tem propriedades de compressão dúctil.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0411378.3A GB0411378D0 (en) | 2004-05-21 | 2004-05-21 | Pharmaceutical compositions |
GB0411378.3 | 2004-05-21 | ||
PCT/GB2005/001931 WO2005112934A1 (en) | 2004-05-21 | 2005-05-18 | Pharmaceutical compositions comprising zd6474 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0511253A true BRPI0511253A (pt) | 2007-11-27 |
BRPI0511253B1 BRPI0511253B1 (pt) | 2020-03-31 |
BRPI0511253B8 BRPI0511253B8 (pt) | 2021-05-25 |
Family
ID=32607743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511253A BRPI0511253B8 (pt) | 2004-05-21 | 2005-05-18 | composição farmacêutica |
Country Status (34)
Country | Link |
---|---|
US (1) | US8067427B2 (pt) |
EP (1) | EP1753431B1 (pt) |
JP (1) | JP4740947B2 (pt) |
KR (1) | KR101192935B1 (pt) |
CN (1) | CN101031303B (pt) |
AR (2) | AR049059A1 (pt) |
AT (1) | ATE439841T1 (pt) |
AU (1) | AU2005244650B2 (pt) |
BR (1) | BRPI0511253B8 (pt) |
CA (1) | CA2565513C (pt) |
CY (1) | CY1109500T1 (pt) |
DE (1) | DE602005016105D1 (pt) |
DK (1) | DK1753431T3 (pt) |
ES (1) | ES2330025T3 (pt) |
GB (1) | GB0411378D0 (pt) |
HK (1) | HK1099220A1 (pt) |
HR (1) | HRP20090547T1 (pt) |
IL (1) | IL178928A (pt) |
ME (2) | ME02778B (pt) |
MX (1) | MXPA06013501A (pt) |
MY (1) | MY138868A (pt) |
NO (1) | NO338324B1 (pt) |
NZ (1) | NZ550931A (pt) |
PL (1) | PL1753431T3 (pt) |
PT (1) | PT1753431E (pt) |
RS (1) | RS51112B (pt) |
RU (1) | RU2383343C2 (pt) |
SA (1) | SA05260133B1 (pt) |
SI (1) | SI1753431T1 (pt) |
TW (1) | TWI355269B (pt) |
UA (1) | UA81732C2 (pt) |
UY (1) | UY28901A1 (pt) |
WO (1) | WO2005112934A1 (pt) |
ZA (1) | ZA200609110B (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2278511B1 (es) * | 2005-07-28 | 2008-06-16 | Laboratorios Almirall S.A. | Comprimidos con perfil de disolucion mejorado. |
DK3039424T3 (da) | 2013-08-28 | 2020-08-31 | Crown Bioscience Inc Taicang | Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
US7173038B1 (en) * | 1999-11-05 | 2007-02-06 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
KR100419555B1 (ko) * | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
WO2003074045A1 (fr) * | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese |
-
2004
- 2004-05-21 GB GBGB0411378.3A patent/GB0411378D0/en not_active Ceased
-
2005
- 2005-05-09 TW TW094114935A patent/TWI355269B/zh active
- 2005-05-17 UY UY28901A patent/UY28901A1/es unknown
- 2005-05-18 CN CN2005800162448A patent/CN101031303B/zh active Active
- 2005-05-18 MX MXPA06013501A patent/MXPA06013501A/es active IP Right Grant
- 2005-05-18 ME MEP-2009-458A patent/ME02778B/me unknown
- 2005-05-18 SA SA05260133A patent/SA05260133B1/ar unknown
- 2005-05-18 WO PCT/GB2005/001931 patent/WO2005112934A1/en active Application Filing
- 2005-05-18 PT PT05744858T patent/PT1753431E/pt unknown
- 2005-05-18 RS RSP-2009/0458A patent/RS51112B/sr unknown
- 2005-05-18 DK DK05744858T patent/DK1753431T3/da active
- 2005-05-18 RU RU2006145357/15A patent/RU2383343C2/ru active Protection Beyond IP Right Term
- 2005-05-18 BR BRPI0511253A patent/BRPI0511253B8/pt active IP Right Grant
- 2005-05-18 UA UAA200613289A patent/UA81732C2/ru unknown
- 2005-05-18 KR KR1020067026603A patent/KR101192935B1/ko active IP Right Grant
- 2005-05-18 JP JP2007517415A patent/JP4740947B2/ja active Active
- 2005-05-18 SI SI200530793T patent/SI1753431T1/sl unknown
- 2005-05-18 DE DE602005016105T patent/DE602005016105D1/de active Active
- 2005-05-18 ES ES05744858T patent/ES2330025T3/es active Active
- 2005-05-18 PL PL05744858T patent/PL1753431T3/pl unknown
- 2005-05-18 US US11/596,979 patent/US8067427B2/en active Active
- 2005-05-18 NZ NZ550931A patent/NZ550931A/en not_active IP Right Cessation
- 2005-05-18 ME MEP-2013-50A patent/ME01505B/me unknown
- 2005-05-18 AU AU2005244650A patent/AU2005244650B2/en active Active
- 2005-05-18 EP EP05744858A patent/EP1753431B1/en active Active
- 2005-05-18 AT AT05744858T patent/ATE439841T1/de active
- 2005-05-18 CA CA2565513A patent/CA2565513C/en active Active
- 2005-05-19 MY MYPI20052271A patent/MY138868A/en unknown
- 2005-05-20 AR ARP050102087A patent/AR049059A1/es not_active Application Discontinuation
-
2006
- 2006-10-29 IL IL178928A patent/IL178928A/en active IP Right Grant
- 2006-11-01 ZA ZA200609110A patent/ZA200609110B/en unknown
- 2006-12-12 NO NO20065735A patent/NO338324B1/no not_active IP Right Cessation
-
2007
- 2007-06-13 HK HK07106372.8A patent/HK1099220A1/xx unknown
-
2009
- 2009-10-13 HR HR20090547T patent/HRP20090547T1/xx unknown
- 2009-10-15 CY CY20091101075T patent/CY1109500T1/el unknown
-
2017
- 2017-11-09 AR ARP170103128A patent/AR110045A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
TNSN08313A1 (fr) | Des formes pharmaceutiques resistantes a la modification | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
WO2007048026A3 (en) | Cgrp peptide antagonists and conjugates | |
BRPI0719393B8 (pt) | composição farmacêutica | |
CL2004000643A1 (es) | Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana. | |
MXPA06012780A (es) | Polimeros a base de acrilico y celulosa y el uso de los mismos para el tratamiento de enfermedades infecciosas. | |
MX2007012645A (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo. | |
ECSP088555A (es) | Composiciones farmacéuticas | |
MA31706B1 (fr) | Formulations galéniques de composés organiques | |
EA201170512A1 (ru) | Композиция для перорального введения | |
AR078082A1 (es) | Composiciones farmaceuticas que comprenden fucanos modificados, metodos y kits relacionados | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
MX2007013468A (es) | Composiciones que contienen tanaproget micronizado. | |
NO20054216L (no) | Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag | |
EP1784173A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES | |
WO2007064620A3 (en) | Compositions comprising a combination of ccr5 and cxcr4 antagonists | |
TW200730190A (en) | New combination to treat liver fibrosis | |
BRPI0511253A (pt) | composição farmacêutica | |
WO2008020314A3 (en) | Statin stabilizing dosage formulations | |
MX2022005388A (es) | Compuestos de pirrolidina y piperidina. | |
DE602005010203D1 (de) | Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol | |
EA200901387A1 (ru) | Фармацевтическая композиция, включающая дезлоратадин | |
AR099137A2 (es) | Formulación para compresión directa y proceso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: GENZYME CORPORATION (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |